BackFate Therapeutics Overview

Fate Therapeutics Current Cash

Latest current cash for FATE: $32M.

Get informed when a big investor buys or sells

+ Follow
Current Cash
$32.43M
↓ 21.38% YoYΔ $-8.82M vs prior year quarter

Peer trimmed avg / median

Loading

Fate Therapeutics Current Cash History

Loading

Fate Therapeutics vs. peers: Current Cash Comparison

Loading

Fate Therapeutics Cash Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Fate Therapeutics (FATE) FAQ

Fate Therapeutics (FATE) currently reports a current cash of $32M as of June 2026. That compares with $41M in the prior-year period — down 21.4% year over year. Use the charts on this page to explore Fate Therapeutics's current cash history and peer comparisons.

Fate Therapeutics's current cash decreased from $41M to $32M — a 21.4% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Fate Therapeutics reported $32M in current cash as of June 2026. That compares with $41M in the prior-year period — down 21.4% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current current cash of $32M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Fate Therapeutics, and consider following FATE for alerts when major investors trade the stock.

Fate Therapeutics is classified in the Healthcare sector. On current cash, it currently shows $32M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing FATE with unrelated industries.